% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • jgmtruth jgmtruth Apr 18, 2013 11:40 PM Flag

    Very impressive.Thanks Mr. Duggan.

    "The completion of the enrollment of our first Phase III study with ibrutinib, ahead of schedule, is an important milestone for our clinical development plan and a real achievement for our company," said Bob Duggan CEO and Chairman of Pharmacyclics. "As of today we have initiated 5 Phase III studies together with our partner Janssen and we currently have registered with the US National Institute of Health 28 clinical trials using ibrutinib. Thus far over 1200 patients have been dosed in our studies and we are making excellent progress in the development of this investigational drug, as underscored by the most recent three Breakthrough Therapy Designations we received from the FDA. It is Pharmacyclics' goal to advance science and drug development in the hopes of making a significant difference for the betterment of patients with serious unmet needs, and we are steadily progressing towards that worthy goal."

    Sentiment: Strong Buy

0.00(0.00%)Apr 23 3:59 PMEDT